Skip to content
Clinical Trials – home
CroatiaBack to Croatia

Clinical trials in Zabok

259 clinical trials in Zabok, Croatia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CroatiaOur site in CroatiaKlinicka-Ispitivanja.hr(opens in a new tab)
Zabok at a glance
259
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

259 trials in Zabok

Open in trial search

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:LY4268989 adipic acid
  • Sponsor:Eli Lilly & Co.

Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001
  • Sponsor:Spyre Therapeutics Inc.

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:ZL-1310
  • Sponsor:Zai Lab (US) LLC

Renal disorder

Recruiting

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Apecotrep
  • Sponsor:Boehringer Ingelheim Espana S.A.

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Long-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

BI 3000202 in Patients with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:BI 3000202
  • Sponsor:Boehringer Ingelheim Espana S.A.

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Apecotrep
  • Sponsor:Boehringer Ingelheim Espana S.A.

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Other cities in Croatia

The busiest research cities in the country

All 26 cities in Croatia

Clinical research in Zabok

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on moderate-to-severe uncontrolled asthma management, evaluating new therapeutic approaches for improving patient outcomes. The trials aim to assess novel treatments for enhancing respiratory function and quality of life.

  • Asthma Control Assessment
  • Respiratory Function Improvement
  • Treatment Efficacy Evaluation

Current studies explore daily oral medication options for adult patients with persistent symptoms.

02 Cardiovascular Medicine

Groundbreaking research in acute coronary syndrome prevention and treatment, investigating innovative therapies to reduce recurrent cardiovascular events in post-heart attack patients.

  • Cardiovascular Event Prevention
  • Post-Heart Attack Care
  • Standard-of-Care Enhancement

The studies focus on developing advanced therapeutic options for improved cardiac outcomes.

03 Cardiac Electrophysiology

Advanced clinical research examining treatment options for patients with atrial fibrillation who cannot receive conventional anticoagulation therapy. These trials evaluate alternative approaches to prevent stroke and systemic embolism.

  • Stroke Prevention
  • Alternative Anticoagulation
  • Cardiac Risk Management

The research aims to expand treatment options for high-risk cardiac patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.